Back

The risks of continuing trastuzumab treatment in HER-2 positive breast cancer after the development of asymptomatic left ventricular dysfunction

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Cardiovascular disease in special populations - cardio-oncology (1) Cardio-Oncology HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Merithza Dominique Joseph

Hospital Ofatma, Port-au-Prince (Haiti)

7 More presentations in this session

Presentation thumbnail
Cardiac manifestations in patients with systemic sclerosis
Associate Professor V. Stoickov (Niska Banja, RS)
Abstract Slides Video
Presentation thumbnail
Association of pre-existing cardiovascular disease with administration of fluoropyrimidine chemotherapy in patients with gastrointestinal malignancies
Doctor A. Abiodun (London, GB)
Abstract Slides Video
Presentation thumbnail
Sodium-glucose cotransporter 2 inhibitor Dapagliflozin reduces systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Patients with non-Hodgkin's lymphoma treated with CAR T-cell therapy are at risk of impaired left ventricular function
Miss E. Polomski (Leiden, NL)
Abstract Slides Video
Presentation thumbnail
Fructose exacerbates anthracycline and HER-2 blocking agent mediated cardiotoxicity through NLRP3 and MyD88 mediated pathways: new roles of sweeteners in cardio-oncology
Doctor V. Quagliariello (Naples, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular disease in special populations - cardio-oncology (1)

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
New onset of left ventricular dysfunction and diastolic dysfunction are uncommon in patients with her2+ breast cancer after completion of cancer therapy.
thumbnail
Congress Presentation
Evaluation of the predictive value of the HFA-ICOS score for cardiotoxicity in breast cancer patients treated with anthracyclines and trastuzumab: a real-world observational study
thumbnail
Congress Presentation
Breast cancer and cardiotoxicity: an update

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources